|
Submit Tools | Thread Tools | Search this Thread | Display Modes |
#1
|
|||
|
|||
RDHL (MC $61 M) FDA deicison on Feb 3 & 2 more NDA filings in 2014 // Float 4 M
RDHL (MC $61 M) FDA deicison on Feb 3 // 2 more NDA filings in 2014 // Float 4 M
RDHL is another brutally Underpriced and Unknown Biotech Stock . Here are the reasons why this low float Gem is a MUST HAVE for every Biotech investor : 1) Very Promising Pipeline with multiple potential Blockbusters 2) FDA decision for first Drug (migraine) on February 3 3) Another 2x NDA Filings soon one in 1Q and one in 2H 2014 4) Another 2 Drugs in Phase 3 5) Very low Burn-rate of only $10 M per year 6) Enough Cash untill mid 2015 Excluding cash from new Partnerships 7) Dirt Cheap with a Market cap of just $61 M 8) Ultra low float with only 4.2 M shares 9) Top Management ( they have one of the most successful director in the pharma area on their board , see below the info to this guy ) I think this low float stock has everything to hit minimum $50++ within 2014 .For me RDHL is currently my top favorite stock in the Biotech sector . GL Redhill (RDHL) Market Cap: $61 M Cash: $14.7 M Price: $9.80 Shares Out: 6.3 M (Management alone holding over 2.6 M shrs) Float: 4.2 M Presentation September 2013 Dan Suesskind, Director Mr. Suesskind, who served 31 years as CFO of Teva Pharmaceutical Industries (NYSE: TEVA) until 2008, had played a pivotal role in the strategic activities of the Israeli generic pharmaceuticals giant, including the acquisition of more than 30 companies. During that period, Teva grew from a small Israeli company with a market cap of $37 million, into a leading global company with a market cap exceeding $34 billion in 2008. Mr. Suesskind is a member of Teva |
Currently Active Users Viewing This Thread: 1 (0 members and 1 guests) | |
Thread Tools | Search this Thread |
Display Modes | |
|
|